#ViiV Healthcare

Anika Noni Rose hosts Season 3 of ViiV Healthcare’s “Being Seen,” covering Black women’s views on stigma, bias, power, HIV and more.

The health and prevention benefits of an undetectable viral load may be uniquely important in the American health care system.

The eight grantees comprise the fourth cohort of the Southern HIV Impact Fund Leadership Development Program.

A new study measures HIV and LGBTQ health equity and finds that HIV care providers are key health leaders. [VIDEO]

Season 2 of ViiV’s podcast explores how queer Black men want to be seen—and how that relates to HIV stigma.

Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.

A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.

ViiV Healthcare teams with stock photography provider Shutterstock to offer a stigma-busting gallery of images.

A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.

Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.

After years of taking daily oral cabotegravir and Edurant, people with suppressed HIV switched to long-acting injectable Cabenuva.

ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.

Virtually, of course. So take a look around.

4% of total U.S. AIDS philanthropy directly addresses African Americans. Plus: Meet the top five funders helping BIPOC communities.